Your VX-770-Boost Helps To Make The General VX-770 Philosophy So Challenging

With a reduction of escalated BEACOPP to six cycles and using a PET-guided consolidation RT strategy, the good balance of risk-benefit may have tipped in favour of the GHSG BEACOPP protocol. Trials directly comparing 6?��?Besc (and not variations of BEACOPP) against ABVD are needed. With PET imaging coming to the forefront of prognostication, we may soon be adjusting HL treatment protocols based not on regional preference but on a risk-adapted http://www.selleck.cn/products/Verteporfin(Visudyne).html PET-2 strategy. Unfortunately, based on current evidence, that time has not yet arrived. Colin Phipps performed the analyis and wrote the paper. Yuh Shan Lee provided input and data. William Hwang provided input and data. ""Although the incidence rate of acute lymphoblastic leukaemia (ALL) is slightly higher in older than in younger adults, response rates to induction chemotherapy and survival rates are poorer. The contribution of disease-related versus treatment-related factors http://www.selleckchem.com/products/VX-770.html remains unclear. We analysed 100 older patients (aged 55�C65?years) treated on the UKALLXII/ECOG2993 trial compared with 1814 younger patients (aged 14�C54?years). Baseline characteristics, induction chemotherapy course, infections, drug reductions and survival outcomes were compared. There were more Philadelphia-positive (Ph+) patients in the older group (28% vs. 17%, P?=?0��02), and a trend towards higher combined cytogenetic risk score (46% vs. 35%, P?=?0��07). The complete remission rate in older patients was worse (73% vs. 93%, P? http://www.selleckchem.com/products/ch5424802.html more infections during induction (81% vs. 70%, P?=?0��05), and drug reductions (46% vs. 28%, P?=?0��0009). Among older patients, Ph+ and cytogenetic risk category as well as infection during induction predicted for worse EFS. Poorer outcomes in these patients are partly due to cytogenetic risk, but there is significant morbidity and mortality during induction chemotherapy with frequent delays and drug reductions. New approaches, including better risk stratification and use of targeted therapies, could improve treatment for these patients. Acute lymphoblastic leukaemia (ALL) is often seen as a disease of the young, but the age-specific annual incidence for individuals over 60?years is 0��9�C1��6 per 100?000, compared to 0��4�C0��6 per 100?000 in those between 25 and 50?years (Larson, 2005). Estimates for the proportion of new cases that present in older patients range from 16% to 31% (Taylor et?al, 1992; Pagano et?al, 2004). The outcomes for older patients have consistently been found to be worse, both in response to induction chemotherapy, and in long term survival. Furthermore, based on an analysis of Surveillance, Epidemiology and End Results (SEER) data from the United States, in contrast to younger patients there has been no significant improvement in outcomes for this group over the last 25?years (Pulte et?al, 2009).